Orthofix Medical Inc. (NASDAQ:OFIX) Shares Sold by Boston Partners

Boston Partners cut its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 44.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,492 shares of the medical device company's stock after selling 31,776 shares during the quarter. Boston Partners owned 0.10% of Orthofix Medical worth $690,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OFIX. Franklin Resources Inc. increased its stake in shares of Orthofix Medical by 37.4% during the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company's stock worth $337,000 after buying an additional 5,702 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Orthofix Medical by 14.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company's stock worth $5,073,000 after acquiring an additional 39,901 shares in the last quarter. Barclays PLC increased its position in shares of Orthofix Medical by 38.8% in the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock valued at $1,912,000 after purchasing an additional 34,210 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Orthofix Medical by 114.9% in the 3rd quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company's stock valued at $1,393,000 after purchasing an additional 47,680 shares in the last quarter. Finally, Kirr Marbach & Co. LLC IN purchased a new stake in shares of Orthofix Medical during the 4th quarter worth $532,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Remove Ads

Insider Buying and Selling

In other news, CFO Julie Andrews sold 4,655 shares of the company's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company's stock, valued at approximately $506,501.68. This represents a 14.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lucas Vitale sold 4,287 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total value of $71,164.20. Following the transaction, the insider now directly owns 135,317 shares in the company, valued at approximately $2,246,262.20. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,999 shares of company stock worth $512,497 in the last 90 days. Company insiders own 2.60% of the company's stock.

Orthofix Medical Stock Performance

Shares of Orthofix Medical stock traded down $0.22 on Wednesday, hitting $16.29. The stock had a trading volume of 141,792 shares, compared to its average volume of 254,026. The stock has a market cap of $635.67 million, a price-to-earnings ratio of -5.20 and a beta of 1.06. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. Orthofix Medical Inc. has a 52-week low of $12.08 and a 52-week high of $20.73. The company's 50 day moving average price is $17.74 and its 200 day moving average price is $17.37.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Roth Mkm reissued a "buy" rating and issued a $22.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Canaccord Genuity Group reiterated a "buy" rating and issued a $24.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, StockNews.com upgraded Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Orthofix Medical has a consensus rating of "Moderate Buy" and a consensus target price of $23.33.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.